BridgeBio Pharma BBIO Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| License and services revenue | $46.61M-61.8% | $121.88M0.0% | $121.83M+4.8% | $116.25M+34.3% | $86.55M-37.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BridgeBio Pharma break its business down?
- BridgeBio Pharma (BBIO) reports revenue by product across 2 parts — Cost of license, services, and royalty revenue and License and services revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does BridgeBio Pharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BridgeBio Pharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
